#
PingChi# from
@MSKCancerCenter presented on the #
final# results of FIH #
NB003# trial, a potent and selective KIT inhibitor in GISTs. Broad spectrum of activity seen in different mutations. Phase 3 trial compared with #
regorafenib# planned.
@ctosociety @Liferaftgroup @myESMO #
ESMO26# #
ESMOAmbassadors#